News Releases

Date Title  
Toggle Summary Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
Toggle Summary Adamis Pharmaceuticals Announces Investor Update Conference Call
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB :  ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
Adamis Pharmaceuticals Announces Investor Update Conference Call
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB :  ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
Toggle Summary Adamis Pharmaceuticals Signs Agreement to Acquire Dry Powder Inhaler Technology From 3M Company
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
Adamis Pharmaceuticals Signs Agreement to Acquire Dry Powder Inhaler Technology From 3M Company
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
Toggle Summary Adamis Pharmaceuticals CEO Provides Update for Shareholders
SAN DIEGO ,  May 3, 2013  /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
Adamis Pharmaceuticals CEO Provides Update for Shareholders
SAN DIEGO ,  May 3, 2013  /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
Toggle Summary Adamis Pharmaceuticals Prevails in License Dispute Litigation
SAN DIEGO ,  Feb. 28, 2013  /PRNewswire/ --  Adamis Pharmaceuticals Corporation  (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
Adamis Pharmaceuticals Prevails in License Dispute Litigation
SAN DIEGO ,  Feb. 28, 2013  /PRNewswire/ --  Adamis Pharmaceuticals Corporation  (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,